AstraZeneca, Qure.ai to bring AI solutions to detect lung cancer

New Delhi, Dec 7 : British-Swedish pharmaceutical firm AstraZeneca on Monday announced a a partnership with Mumbai-based Qure.ai, a healthcare startup to integrate innovative artificial intelligence (AI) solutions for the early detection of lung cancer in patients across India.
AstraZeneca and Qure.ai will be covering the emerging market regions in Latin America, Asia, Middle East and Africa.
The partnership aims to harness and scale-up the use of this technology to improve early-stage detection of lung cancer in the markets involved, to reduce mortality rates and improve patient outcomes.
As part of the strategic collaboration, AstraZeneca will work with Qure.ai to explore the application of deep learning algorithms to identify patients with suspicious radiographic lung abnormalities and support their referral to arrive at a firm diagnosis.
“Innovations such as this are critical for boosting the capabilities of healthcare ecosystem, and this partnership supports our bold ambition of eliminating cancer as a cause of death,” Leon Wang, AstraZeneca EVP International and Country President, China, said in a statement.
The collaboration will also focus on overcoming barriers that limit access to diagnostic tools to support early lung cancer detection.